Stephen Ross

Professor of Psychiatry

Data updated

Papers

16 publications

Trials

0 clinical trials

Links

Research Footprint

Stephen Ross appears in 16 tracked papers (2016–2026), most studied alongside Psilocybin, MDMA and LSD, across Depressive Disorders, Anxiety Disorders and Palliative & End-of-Life Distress.

Most-cited paper: Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial (1678 citations).

Frequent co-authors: Gabrielle Agin-Liebes, Alison Bossis and Susan Mennenga.

Background & Research

Stephen Ross is a psychiatrist and clinical researcher based at NYU Langone who has been a prominent investigator in contemporary clinical research on psilocybin-assisted psychotherapy. He trained and practised in general and addiction psychiatry and has led and co‑authored multiple clinical trials and follow‑up studies examining psilocybin for psychiatric and existential distress in patients with life‑threatening cancer, for alcohol use disorder, and for changes in religious and spiritual attitudes. His work blends controlled clinical trial methodology with detailed qualitative and phenomenological analyses of patient experience.
Ross's contributions include designing and running early-phase clinical protocols, publishing long‑term follow‑up and individual case analyses, and exploring therapeutic mechanisms such as mystical‑type and meaning‑making experiences. He has collaborated with other major figures and centres in the field (including multi‑site teams) and has emphasised careful safety monitoring, integration work, and clinical interpretation of subjective outcomes. His scholarship and public engagement have helped shape clinical and ethical conversations about the therapeutic use of psychedelic compounds in psychiatry.

Affiliations

Institutions, companies, and organisations Stephen Ross is associated with.